Opinion|Videos|March 14, 2025
Future Directions and Overcoming Challenges in BTK Inhibitor Therapy
Panelists discuss challenges oncologists face in managing treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), including balancing efficacy with adverse effect profiles, and highlight strategies such as multidisciplinary collaboration and access to updated treatment guidelines to address these issues while also expressing eagerness for future advancements in Bruton tyrosine kinase (BTK) inhibitors and the need for further research to refine treatment strategies and improve patient outcomes.
Advertisement
Episodes in this series
- What are other challenges oncologists face when managing treatment-naive patients with CLL and MCL, and what strategies or resources can help overcome these challenges?
- What are you most eager to see regarding the future use of BTK inhibitors, and what areas of research or collaboration are needed to further improve patient outcomes?
Advertisement
Related to this article
As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.
Patients on tegoprubart reported fewer transplant-related symptoms and better quality of life at 12 months than those on tacrolimus in phase 2 BESTOW.
Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.
Mayo Clinic case-control study links higher birth weight and childhood obesity to greater non-Hodgkin lymphoma risk, while longer breastfeeding may lower odds.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
3
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
4
Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk
5